Novartis pays US$12 billion for Avidity’s lead antibody–oligonucleotide drugs
A
Asher Mullard
Article Details
Journal
Nature Reviews Drug Discovery
Volume / Issue
Vol. 24, Issue 12
Published
December 01, 2025
Pages
896-896
ISSN
1474-1776
Publisher
Springer Science and Business Media LLC
Journal Info
Nature Reviews Drug Discovery
Springer Science and Business Media LLC
ISSN: 1474-1776 Q1 Medicine
Authors (1)
A
Asher Mullard
Related Articles from this Journal
Can multispecific biologics break the efficacy ceiling?
Asher Mullard
Jul 2026
10.1038/d41573-026-00106-5
Novel drug targets in 2025
Sorin Avram, Liliana Halip et al.
Jul 2026
10.1038/d41573-026-00102-9
The unglamourous AI wins that are quietly transforming drug discovery and development
Asher Mullard
Jul 2026
10.1038/d41573-026-00099-1
Upcoming FDA approval decisions in Q3 2026
Swetha Kota
Jul 2026
10.1038/d41573-026-00103-8
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
Asher Mullard
Jul 2026
10.1038/d41573-026-00101-w